Eravacycline Activity Against KPC-2 and NDM-1 Klebsiella Pneumoniae

42 K2N1-CRKP strains from a 2026 study were analyzed for susceptibility to eravacycline and its combinations with other antibiotics. The dataset contains in vitro and in vivo results, including MIC values and synergistic activity assessments. It was authored by Xiaojie Zhao to evaluate therapeutic options against carbapenem-resistant Klebsiella pneumoniae.

Use Cases

• Analyze eravacycline MIC50/90 values and susceptibility rates across the 42 ST11 K2N1-CRKP strains.
• Model synergistic interactions between eravacycline and polymyxin B using in vitro time-kill assay results.
• Correlate in vitro susceptibility data with in vivo survival outcomes from the Galleria mellonella infection model.
• Compare the efficacy of eravacycline combined with ceftazidime-avibactam, meropenem, or amikacin against dual-resistant strains.

Strengths

• Data is derived from 42 clinically relevant K2N1-CRKP strains, providing a focused sample.
• Includes both in vitro (MIC, synergy) and in vivo (Galleria mellonella model) experimental results.
• Clear susceptibility metrics are provided, such as 92.8% susceptibility to eravacycline and MIC50/90 of 1 μg/mL.
• Published under a permissive CC BY 4.0 license in 2026, ensuring recent and reusable data.

Limitations

• The dataset is small, containing results for only 42 bacterial strains, limiting statistical power.
• All strains belong to a single sequence type (ST11), which may not represent the full genetic diversity of K2N1-CRKP.
• The 16.1 KB file size indicates a very limited scope, likely containing summary tables rather than raw experimental data.

Provenance

Source

figshare, authored by Xiaojie Zhao.

Collection Method

Laboratory analysis of 42 K2N1-CRKP strains, including susceptibility testing, synergy assays, and an in vivo infection model.

Time Range

Study published in 2026.

Freshness

Last updated March 25, 2026.